+

WO1992005266A3 - Cellules d'encapsidation - Google Patents

Cellules d'encapsidation Download PDF

Info

Publication number
WO1992005266A3
WO1992005266A3 PCT/US1991/006852 US9106852W WO9205266A3 WO 1992005266 A3 WO1992005266 A3 WO 1992005266A3 US 9106852 W US9106852 W US 9106852W WO 9205266 A3 WO9205266 A3 WO 9205266A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
retrovirus
recombinant
particular cell
cell type
Prior art date
Application number
PCT/US1991/006852
Other languages
English (en)
Other versions
WO1992005266A2 (fr
Inventor
Douglas J Jolly
Jack R Barber
James G Respess
Stephen M W Chang
Original Assignee
Viagene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viagene Inc filed Critical Viagene Inc
Priority to CA002092195A priority Critical patent/CA2092195C/fr
Priority to AU88424/91A priority patent/AU665176B2/en
Publication of WO1992005266A2 publication Critical patent/WO1992005266A2/fr
Publication of WO1992005266A3 publication Critical patent/WO1992005266A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/30—Rearing or breeding invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13051—Methods of production or purification of viral material
    • C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Environmental Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention permet la production de rétrovirus recombinés (particules vectorielles rétrovirales) à partir de cellules productrices plus sûres et d'un titre supérieur à la normale. De plus, l'invention concerne des procédés de production de cellules auxiliaires qui, lorsqu'un génome de rétrovirus recombiné est introduit afin de produire une lignée productrice, produisent des particules dont les cibles sont des types particuliers de cellules. De plus, l'invention concerne des procédés de production de systèmes de rétrovirus recombinés adaptés pour infecter un type particulier de cellules, tel qu'une tumeur, par liaison du rétrovirus ou du rétrovirus recombiné dans le type particulier de cellules. En outre, l'invention concerne des procédés de production de rétrovirus recombinés s'intégrant dans un petit nombre spécifique d'endroits dans le génome hôte, et des procédés de production de rétrovirus recombinés à partir d'animaux transgéniques.
PCT/US1991/006852 1990-09-21 1991-09-20 Cellules d'encapsidation WO1992005266A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002092195A CA2092195C (fr) 1990-09-21 1991-09-20 Lignee cellulaire a encapsidation retrovirale
AU88424/91A AU665176B2 (en) 1990-09-21 1991-09-20 Packaging cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58660390A 1990-09-21 1990-09-21
US586,603 1990-09-21

Publications (2)

Publication Number Publication Date
WO1992005266A2 WO1992005266A2 (fr) 1992-04-02
WO1992005266A3 true WO1992005266A3 (fr) 1992-07-23

Family

ID=24346413

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/006852 WO1992005266A2 (fr) 1990-09-21 1991-09-20 Cellules d'encapsidation

Country Status (5)

Country Link
EP (3) EP0854193A1 (fr)
JP (3) JPH06500923A (fr)
AU (2) AU665176B2 (fr)
CA (1) CA2092195C (fr)
WO (1) WO1992005266A2 (fr)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5662896A (en) * 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
US6027722A (en) * 1990-10-25 2000-02-22 Nature Technology Corporation Vectors for gene transfer
US5512421A (en) * 1991-02-19 1996-04-30 The Regents Of The University Of California Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors
WO1993020221A1 (fr) * 1992-04-03 1993-10-14 Young Alexander T Therapie genique utilisant des vecteurs viraux cibles
AU4259193A (en) * 1992-04-28 1993-11-29 Frank Andreas Harald Meyer Medicament for the gene-therapeutic treatment of human beings, animals and plants, especially to block virus multiplication and carcinogenes and process for producing the medicament
AU689755B2 (en) 1992-09-22 1998-04-09 Biofocus Discovery Limited Recombinant viruses displaying a nonviral polypeptide on their external surface
AU688292B2 (en) * 1992-11-09 1998-03-12 United States Government as represented by the Department of Health and Human Services, The Targetable vector particles
US6534051B1 (en) 1992-11-20 2003-03-18 University Of Medicine And Dentistry Of New Jersey Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins
CA2156725A1 (fr) * 1993-02-22 1994-09-01 Warren S. Pear Production de retrovirus sans auxiliaire, a haut titre, par transfection transitoire
AU699706C (en) 1993-03-12 2000-01-13 Creighton University Improved vectors for gene therapy
FR2707091B1 (fr) 1993-06-30 1997-04-04 Cohen Haguenauer Odile Vecteur rétroviral pour le transfert et l'expression de gènes dans des cellules eucaryotes.
FR2716459B1 (fr) * 1994-02-22 1996-05-10 Univ Paris Curie Système hôte-vecteur utilisable en thérapie génique.
FR2716461A1 (fr) * 1994-02-22 1995-08-25 Univ Paris Curie Système hôte-vecteur utilisable en thérapie génique.
US6013517A (en) 1994-05-09 2000-01-11 Chiron Corporation Crossless retroviral vectors
EP0772689B1 (fr) 1994-05-09 2007-12-19 Oxford Biomedica (UK) Limited Vecteurs retroviraux a taux de recombinaison reduit
EP0763123A4 (fr) * 1994-06-07 1998-08-12 Immunomedics Inc Vecteurs retroviraux sans danger, leur production et utilisation
CA2196208A1 (fr) * 1994-08-17 1996-02-22 Michael Pensiero Vecteurs retroviraux produits par des lignees de cellules productrices resistantes a la lyse par le serum humain
US5698446A (en) * 1994-09-07 1997-12-16 Chiron Corporation Methods and compositions for inhibiting production of replication competent virus
ES2293643T5 (es) * 1994-10-20 2012-02-02 Institut Pasteur Secuencias nucleotídicas de antígenos retrovíricos vih-1 del grupo (o subgrupo) o.
FR2727429B1 (fr) * 1994-11-30 1997-11-28 Haguenauer Odile Cohen Lignees d'encapsidation et vecteurs d'expression pour la transcomplementation de vecteurs retroviraux defectifs
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
US5681746A (en) * 1994-12-30 1997-10-28 Chiron Viagene, Inc. Retroviral delivery of full length factor VIII
US5910434A (en) * 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
US6365344B1 (en) 1996-01-23 2002-04-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
WO1997027213A1 (fr) 1996-01-23 1997-07-31 The Board Of Trustees Of The Leland Stanford Junior University Procedes servant a rechercher par criblage des peptides effecteurs et des molecules d'arn transdominants
US6723531B2 (en) 1996-04-05 2004-04-20 The Salk Institute For Biological Studies Method for modulating expression of exogenous genes in mammalian systems, and products related thereto
DE69739286D1 (de) * 1996-05-06 2009-04-16 Oxford Biomedica Ltd Rekombinationsunfähige retrovirale vektoren
US5928638A (en) * 1996-06-17 1999-07-27 Systemix, Inc. Methods for gene transfer
US6133027A (en) * 1996-08-07 2000-10-17 City Of Hope Inducible expression system
US5739018A (en) * 1996-08-07 1998-04-14 The Regents Of The University Of California Packaging cell lines for pseudotyped retroviral vectors
EP0935659A1 (fr) 1996-09-17 1999-08-18 Chiron Corporation Compositions et procedes de traitement de maladies intracellulaires
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US6300488B1 (en) 1997-07-10 2001-10-09 The Salk Institute For Biological Studies Modified lepidopteran receptors and hybrid multifunctional proteins for use in transcription and regulation of transgene expression
AU8692598A (en) 1997-08-04 1999-02-22 Calydon, Inc. A human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof
JP4472866B2 (ja) 1997-11-06 2010-06-02 カイロン ソチエタ ア レスポンサビリタ リミタータ ナイセリア抗原
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
EP2210945B1 (fr) 1998-01-14 2013-06-26 Novartis Vaccines and Diagnostics S.r.l. Antigènes de Neisseria meningitidis
ES2294629T3 (es) 1998-05-01 2008-04-01 Novartis Vaccines And Diagnostics, Inc. Antigenos de neisseria y composiciones.
US6333318B1 (en) 1998-05-14 2001-12-25 The Salk Institute For Biological Studies Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto
EP1121437B1 (fr) 1998-10-15 2008-02-20 Novartis Vaccines and Diagnostics, Inc. Genes regules dans les cellules du cancer du sein metastatique et du cancer du colon
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
EP1141331B1 (fr) 1998-12-16 2008-09-17 Novartis Vaccines and Diagnostics, Inc. KINASE DEPENDANT DE LA CYCLINE DE TYPE HUMAIN (hPNQALRE)
US6410316B1 (en) 1999-03-15 2002-06-25 Chiron Corporation Methods for producing a vector producing cell line utilizing a high multiplicity of transduction
BR0010130A (pt) 1999-04-30 2002-06-04 Chiron Spa Antìgenos de neisseria conservados
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
US7504253B2 (en) 1999-06-11 2009-03-17 The Burnham Institute For Medical Research Nucleic acid encoding proteins involved in protein degradation, products and methods related thereof
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
US7057015B1 (en) 1999-10-20 2006-06-06 The Salk Institute For Biological Studies Hormone receptor functional dimers and methods of their use
CN1433470A (zh) 1999-10-29 2003-07-30 启龙股份公司 奈瑟球菌的抗原性肽
ES2335386T3 (es) 1999-11-18 2010-03-26 Novartis Vaccines And Diagnostics, Inc. Gen fgf-21 humano y productos de expresion genica.
WO2001052885A1 (fr) 2000-01-17 2001-07-26 Chiron Spa Vaccin a base de vesicule de membrane externe (omv) comprenant des proteines de membrane externe du serogroupe b de n. meningitis
PT1947187E (pt) 2000-02-28 2011-07-04 Novartis Vaccines & Diagnostic Expressões híbridas de proteínas de neisseria
EP2075255A1 (fr) 2000-03-08 2009-07-01 Novartis Vaccines and Diagnostics, Inc. Gène FGF-23 humain et produits d'expression de gènes
DK1274464T3 (da) 2000-03-13 2012-01-23 Engene Inc Sammensætninger og fremgangsmåder til regulering af proteinekspression i tarm
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
GB0024550D0 (fr) 2000-10-06 2000-11-22 Oxford Biomedica Ltd
ES2330083T3 (es) 2000-10-27 2009-12-04 Novartis Vaccines And Diagnostics S.R.L. Acidos nucleicos y proteinas de estreptococos de los grupos a y b.
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
AU2002303261A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
WO2002081641A2 (fr) 2001-04-06 2002-10-17 Georgetown University Gene scc-112 et utilisations diagnostique et therapeutique de ce gene
AU2002258728A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
CA2344208A1 (fr) 2001-04-30 2002-10-30 Oxford Biomedica (Uk) Limited Methode
AU2002366592B2 (en) 2001-12-12 2008-01-10 Novartis Vaccines And Diagnostics S.R.L. Immunisation against Chlamydia trachomatis
JP4598398B2 (ja) 2002-02-01 2010-12-15 オックスフォード バイオメディカ （ユーケー） リミテッド ウイルスベクター
US7138512B2 (en) 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
EP1562982B1 (fr) 2002-11-15 2010-05-05 Novartis Vaccines and Diagnostics S.r.l. Proteines de surface inattendues du neisseria meningitidis
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
DK1736541T3 (da) 2004-03-29 2013-05-06 Galpharma Co Ltd Nyt modificeret galectin 9-protein og anvendelse heraf
EP1769078A1 (fr) * 2004-07-01 2007-04-04 VIRxSYS Corporation Lignee cellulaire d'encapsidation de vecteurs
CA2524619A1 (fr) 2005-11-22 2007-05-22 Ottawa Health Research Institute Nouvelles cellules souches, sequences nucleotides et proteines provenant de celles-ci
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
US20110206692A1 (en) 2006-06-09 2011-08-25 Novartis Ag Conformers of bacterial adhesins
JP2010510772A (ja) 2006-11-27 2010-04-08 パトリス リミテッド 新生細胞における新規なグリコシル化ペプチド標的
RU2471487C2 (ru) 2007-02-06 2013-01-10 Тай Джун ЙОО Лечение и предупреждение нейродегенеративных заболеваний с использованием генной терапии
US8673859B2 (en) 2007-03-20 2014-03-18 New York University GM-CSF cosmeceutical compositions and methods of use thereof
EP2185694A2 (fr) 2007-08-02 2010-05-19 California Stem Cell, Inc. Cellules progénitrices neuronales et procédés de dérivation et de purification de cellules progénitrices neuronales de cellules souches embryonnaires
US20120040367A1 (en) 2007-10-15 2012-02-16 The University Of Queensland Construct system and uses therefor
US8877896B2 (en) 2008-02-15 2014-11-04 Tufts University Compositions, methods and kits for modeling, diagnosing, and treating complement disorders
AU2009215118B2 (en) 2008-02-15 2015-01-22 Tufts University A humanized model of membrane attack complex (MAC) formation on murine retina and compositions, kits and methods for treatment of macular degeneration
US8999919B2 (en) 2008-10-22 2015-04-07 Trustees Of Dartmouth College Compositions and methods for inhibiting the interaction between CFTR and CAL
US8211487B2 (en) 2008-11-26 2012-07-03 Srinivasan Damodaran Inhibition of ice crystal growth
ES2571235T3 (es) 2009-04-10 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3
PT2426148E (pt) 2009-04-27 2015-10-26 Kyowa Hakko Kirin Co Ltd Anticorpo anti-rá-il-3 para se utilizar no tratamento de tumores do sangue
US10316333B2 (en) * 2009-06-17 2019-06-11 Tocagen Inc. Producer cells for replication competent retroviral vectors
WO2011060233A1 (fr) 2009-11-11 2011-05-19 The Trustees Of The University Of Pennsylvania Anticorps anti-tem1 et leurs utilisations
GB0920775D0 (en) 2009-11-26 2010-01-13 King S College Cells
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
CA2843684A1 (fr) 2010-08-13 2012-02-16 Tufts University Compositions, trousses et methodes de traitement de la degenerescence maculaire au moyen de la proteine cd59 soluble independante de la membrane
US9198975B2 (en) 2010-12-01 2015-12-01 The University Of North Carolina At Chapel Hill Methods and compositions for targeting sites of neovascular growth
US9279002B2 (en) 2011-09-15 2016-03-08 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Immunotherapy and diagnosis of mucormycosis using CotH
US9783610B2 (en) 2012-04-27 2017-10-10 The Trustees Of The University Of Pennsylvania Anti-tumor endothelial marker-1 (TEM1) antibody variants and uses thereof
WO2014124334A2 (fr) 2013-02-08 2014-08-14 Misfolding Diagnostics, Inc. Anticorps anti-transthyrétine et leurs utilisations
WO2014197535A1 (fr) 2013-06-04 2014-12-11 Virginia Commonwealth University Cytokines thérapeutiques recombinantes contre le cancer
US9750823B2 (en) 2013-06-04 2017-09-05 Virginia Commonwealth University Use of a truncated CCN1 promoter for cancer diagnostics, therapeutics and theranostics
US9701985B2 (en) 2013-06-04 2017-07-11 Virginia Commonwealth University mda-9/syntenin promoter to image and treat metastatic cancer cells
EP3003393A4 (fr) 2013-06-04 2017-01-11 The Johns Hopkins University Produits de recombinaison d'acides nucléiques tripartites utilisables dans le cadre de la théranostique du cancer
EP3004357A4 (fr) 2013-06-04 2017-01-11 The Johns Hopkins University Expression en surface del'avidine/streptavidine, médiée par peg-prom
US20160152952A1 (en) 2013-06-25 2016-06-02 Temple University-Of The Commonwealth System Of Higher Education Cortical Bone-Derived Stem Cells
GB201318804D0 (en) 2013-10-24 2013-12-11 Adaptimmune Ltd Vectors for transgene expression
WO2015148683A1 (fr) 2014-03-26 2015-10-01 Tocagen Inc. Vecteur rétroviral à activité de stimulation immunitaire
EP3186269B1 (fr) 2014-08-28 2021-03-10 Tufts University Compositions, procédés et kits pour le traitement des troubles liés au complément
GB201415344D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Protein
US9901639B2 (en) 2015-02-13 2018-02-27 Temple University—Of the Commonwealth System of Higher Education Bone marrow origin progenitor cell or endothelial progenitor cell in combination with DNMT1 gene therapy for vascular repair in metabolic disease
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
KR20180083437A (ko) 2015-12-09 2018-07-20 애드메더스 백신스 피티와이 리미티드 치료를 위한 면역조절용 조성물
GB201603372D0 (en) * 2016-02-26 2016-04-13 Ucl Business Plc Cell
BR112018070948A2 (pt) 2016-04-13 2019-01-29 Orimabs Ltd anticorpos anti-psma e utilização dos mesmos
EP3299460A1 (fr) 2016-09-26 2018-03-28 Johann Wolfgang Goethe-Universität Frankfurt am Main Nouveaux composes et procedes destines a moduler l'expression de l'ubiquitination
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
CA3090997A1 (fr) 2018-02-12 2019-08-15 Trustees Of Tufts College Cd59 pour inhiber l'activation d'inflammasome
EP3781130A4 (fr) 2018-04-11 2022-01-26 Precision Molecular Inc. Combinaisons thérapeutiques pour le traitement du cancer
AU2020328507A1 (en) 2019-08-12 2022-03-17 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells
WO2021074695A1 (fr) 2019-10-16 2021-04-22 Avacta Life Sciences Limited FRACTIONS DE MÉDICAMENTS BISPÉCIFIQUES DE L'INHIBITEUR DE PD-L1 ET DE L'INHIBITEUR DE TGFβ
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
WO2022234003A1 (fr) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Polypeptides se liant à cd33 avec protéine stefin a
EP4413038A1 (fr) 2021-10-07 2024-08-14 Avacta Life Sciences Limited Affimers de liaison à pd-l1
TW202332694A (zh) 2021-10-07 2023-08-16 英商阿凡克塔生命科學公司 血清半衰期延長之ｐｄ－ｌ１結合多肽
WO2023089564A1 (fr) 2021-11-19 2023-05-25 Janssen Biotech, Inc. Méthode de traitement d'une atrophie géographique avec un vecteur de thérapie génique exprimant cd59 soluble
KR20250006965A (ko) 2022-04-29 2025-01-13 퓨리노미아 바이오테크, 아이엔씨. 호산구에 의해 유발되는 질환 및 장애의 치료를 위한 방법 및 조성물
WO2025074268A1 (fr) 2023-10-02 2025-04-10 Janssen Biotech, Inc. Méthodes pour traiter la dégénérescence maculaire

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988008454A1 (fr) * 1987-04-23 1988-11-03 State Of Oregon Acting By And Through The State Bo Procede permettant d'amplifier l'expression et la transmission de genes clones dans des cellules eucaryotiques
EP0386882A1 (fr) * 1989-02-06 1990-09-12 Dana Farber Cancer Institute Provirus d'HIV défectif pour l'empaquetage, lignées cellulaires et leur utilisation
WO1991002805A2 (fr) * 1989-08-18 1991-03-07 Viagene, Inc. Retrovirus de recombinaison apportant des constructions de vecteur a des cellules cibles

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1038306A (zh) * 1988-03-21 1989-12-27 维吉恩公司 重组反转录病毒
WO1991019803A1 (fr) * 1990-06-19 1991-12-26 Applied Biotechnology, Incorporated Particules virales autoassemblees defectueuses qui ne se propagent pas d'elles-memes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988008454A1 (fr) * 1987-04-23 1988-11-03 State Of Oregon Acting By And Through The State Bo Procede permettant d'amplifier l'expression et la transmission de genes clones dans des cellules eucaryotiques
EP0386882A1 (fr) * 1989-02-06 1990-09-12 Dana Farber Cancer Institute Provirus d'HIV défectif pour l'empaquetage, lignées cellulaires et leur utilisation
WO1991002805A2 (fr) * 1989-08-18 1991-03-07 Viagene, Inc. Retrovirus de recombinaison apportant des constructions de vecteur a des cellules cibles

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Journal of Virology, vol. 64, no. 3, March 1990, F.-L. COSSET et al.: "A new avian leukosis virus-based packaging cell line that uses two separate transcomplementing helper genomes", pages 1070-1078, see the whole document, specially page 1076, column 2 *
Nucleic Acids Research, vol. 18, no. 12, 25 June 1990, J.P. MORGENSTERN et al.: "Advanced mammalian gene tranfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line", pages 3587-3596, see the whole document *

Also Published As

Publication number Publication date
EP1285967A2 (fr) 2003-02-26
AU8842491A (en) 1992-04-15
JP2003159062A (ja) 2003-06-03
AU665176B2 (en) 1995-12-21
CA2092195C (fr) 2000-04-18
CA2092195A1 (fr) 1992-03-22
WO1992005266A2 (fr) 1992-04-02
AU690427B2 (en) 1998-04-23
EP1285967A3 (fr) 2005-03-02
JP4092278B2 (ja) 2008-05-28
EP0549723A1 (fr) 1993-07-07
AU4798496A (en) 1996-06-20
EP0854193A1 (fr) 1998-07-22
JP2004041234A (ja) 2004-02-12
JPH06500923A (ja) 1994-01-27

Similar Documents

Publication Publication Date Title
WO1992005266A3 (fr) Cellules d'encapsidation
GB2325003A (en) Rectroviral vectors
CA2328404A1 (fr) Nouvelles cellules lentivirales d'encapsidation
IL204703A0 (en) Immunogenic composition comprising recombinat vector, recombinat cell, transduced with the recombinat vector and a vector
CA2074355A1 (fr) Plants de mais transgeniques fertiles
WO1996037623B1 (fr) Vecteurs retroviraux
BR9709487A (pt) Moléculas de ácido nucléico que codificam enzimas de trigo que est o envolvidas nas síntese de amigo
WO2000017365A3 (fr) Systeme binaire d'expression virale dans des plantes
CA2130454A1 (fr) Production de plantes viro-resistantes par l'introduction d'arn viral sens non traduisible
HUP9801855A2 (hu) Növényekben szintetizált és azokból kinyert módosított keményítő, valamint eljárás előállításukra
GB2331522A (en) Lentiviral vectors
WO1998044097A3 (fr) Procede permettant une expression renforcee de produits geniques etrangers et endogenes chez des vegetaux
NO163620C (no) Ethylenpolymerer inneholdende enheter avledet fra maleinsyreanhydrid, fremgangsmaate for fremstilling av pylymerene og deres anvendelse for fremstilling av folier.
NO975813D0 (no) Innkapslede celler som produserer virale partikler
HU9200260D0 (en) Plazmide-producing process for producing posttransformed retrovirus gene, plazmide from them and products from them
WO2000000600A3 (fr) Vecteurs lentiviraux
WO1996007749A3 (fr) Procedes et compositions d'inhibition de la production de virus aptes a la replication
CA2329510A1 (fr) Sequences de type promoteur exprimees dans les antheres et les pollens
GR3015892T3 (en) Virus resistant plants having a viral coat protein.
DK0817860T3 (da) Pseudotype retrovirale partikler
RU2006123079A (ru) Вирусные частицы, содержащие вектор, происходящий из альфавируса, и способ получения указанной вирусной частицы
EP0101288A3 (fr) Aryl(aryloxy- ou arylthio)azolométhanes, leurs préparation et utilisation
CA2004646A1 (fr) Protease, transcriptase inverse et endonucleases de retrovirus, et methode de production de ces enzymes
EP0147145A3 (fr) Cellules hôtes de streptomycète à activité de restriction réduite
NZ196835A (en) Total synthesis of irs 4sr 5rs-4-(4,8-dimethyl-5-hydroxy-7-nonenyl)-4-methyl-3,8-dioxabicyclo-(3.2.1)octane-1-acetic acid

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BB BG BR CA CS FI HU JP KP KR LK MC MG MN MW NO PL RO SD SU

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU ML MR NL SE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/10-10/10,DRAWINGS,REPLACED BY NEW PAGES 1/10-10-10;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BB BG BR CA CS FI HU JP KP KR LK MC MG MN MW NO PL RO SD SU

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2092195

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1991919095

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1991919095

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1991919095

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载